Rockefeller Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Rockefeller Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-382	Closed	-$6K	–	4122
2021 Q3	$6K	Hold	382	–	–	﹤0.01%	3141
2021 Q2	$3K	Hold	382	–	–	﹤0.01%	3212
2021 Q1	$4K	Buy	+382	New	+$4.72K	﹤0.01%	2990
2020 Q4	–	Sell	-5,000	Closed	-$71K	–	3073
2020 Q3	$71K	Hold	5,000	–	–	﹤0.01%	1396
2020 Q2	$40K	Buy	+5,000	New	+$30.9K	﹤0.01%	1465

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Rockefeller Capital Management's TRIL Position: Q4 2021 in Review

Rockefeller Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 382 shares — an estimated $6K sold.

Rockefeller Capital Management first reported a position in TRIL in Q2 2020 and held it in 5 quarters. The position peaked at $71K in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Rockefeller Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Rockefeller Capital Management sold 382 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $6K.
Rockefeller Capital Management first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 5 quarters.
Rockefeller Capital Management's Trillium Therapeutics Inc. position peaked at $71K in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Rockefeller Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.